Page 17 - Read Online

Page 8 of 9 Kovacs et al. Vessel Plus 2018;2:15 I http://dx.doi.org/10.20517/2574-1209.2018.06

32. Bertos NR, Wang AH, Yang XJ. Class II histone deacetylases: structure, function, and regulation. Biochem Cell Biol 2001;79:243-52.
33. Parra M, Verdin E. Regulatory signal transduction pathways for class IIa histone deacetylases. Curr Opin Pharmacol 2010;10:454-60.
34. Valenzuela-Fernandez A, Cabrero JR, Serrador JM, Sanchez-Madrid F. HDAC6: a key regulator of cytoskeleton, cell migration and
cell-cell interactions. Trends Cell Biol 2008;18:291-7.
35. Guardiola AR, Yao TP. Molecular cloning and characterization of a novel histone deacetylase HDAC10. J Biol Chem 2002;277:3350-6.
36. Gao L, Cueto MA, Asselbergs F, Atadja P. Cloning and functional characterization of HDAC11, a novel member of the human histone
deacetylase family. J Biol Chem 2002;277:25748-55.
37. Frye RA. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem Biophys Res Commun 2000;273:793-8.
38. Haigis MC, Guarente LP. Mammalian sirtuins--emerging roles in physiology, aging, and calorie restriction. Genes Dev 2006;20:2913-
21.
39. Min J, Landry J, Sternglanz R, Xu RM. Crystal structure of a SIR2 homolog-NAD complex. Cell 2001;105:269-79.
40. Denu JM. The Sir 2 family of protein deacetylases. Curr Opin Chem Biol 2005;9:431-40.
41. Frye RA. Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD
and may have protein ADP-ribosyltransferase activity. Biochem Biophys Res Commun 1999;260:273-9.
42. Drazic A, Myklebust LM, Ree R, Arnesen T. The world of protein acetylation. Biochim Biophys Acta 2016;1864:1372-401.
43. Jenuwein T, Allis CD. Translating the histone code. Science 2001;293:1074-80.
44. Ruthenburg AJ, Li H, Patel DJ, Allis CD. Multivalent engagement of chromatin modifications by linked binding modules. Nat Rev Mol
Cell Biol 2007;8:983-94.
45. Wang Z, Zang C, Cui K, Schones DE, Barski A, Peng W, Zhao K. Genome-wide mapping of HATs and HDACs reveals distinct
functions in active and inactive genes. Cell 2009;138:1019-31.
46. Spange S, Wagner T, Heinzel T, Kramer OH. Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int J
Biochem Cell Biol 2009;41:185-98.
47. Caron C, Boyault C, Khochbin S. Regulatory cross-talk between lysine acetylation and ubiquitination: role in the control of protein
stability. Bioessays 2005;27:408-15.
48. Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for
disease and therapy. Nat Rev Genet 2009;10:32-42.
49. Bassett SA, Barnett MP. The role of dietary histone deacetylases (HDACs) inhibitors in health and disease. Nutrients 2014;6:4273-301.
50. Lawless MW, Norris S, O’Byrne KJ, Gray SG. Targeting histone deacetylases for the treatment of disease. J Cell Mol Med 2009;13:826-
52.
51. Tang J, Yan H, Zhuang S. Histone deacetylases as targets for treatment of multiple diseases. Clin Sci (Lond) 2013;124:651-62.
52. Pan LN, Lu J, Huang B. HDAC inhibitors: a potential new category of anti-tumor agents. Cell Mol Immunol 2007;4:337-43.
53. Walkinshaw DR, Yang XJ. Histone deacetylase inhibitors as novel anticancer therapeutics. Curr Oncol 2008;15:237-43.
54. Adcock IM. HDAC inhibitors as anti-inflammatory agents. Br J Pharmacol 2007;150:829-31.
55. Leoni F, Zaliani A, Bertolini G, Porro G, Pagani P, Pozzi P, Dona G, Fossati G, Sozzani S, Azam T, Bufler P, Fantuzzi G, Goncharov
I, Kim SH, Pomerantz BJ, Reznikov LL, Siegmund B, Dinarello CA, Mascagni P. The antitumor histone deacetylase inhibitor
suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci U S A
2002;99:2995-3000.
56. Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM, Barczyk A, Hayashi S, Adcock IM, Hogg JC, Barnes PJ. Decreased histone
deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005;352:1967-76.
57. Ito K, Charron CE, Adcock IM. Impact of protein acetylation in inflammatory lung diseases. Pharmacol Ther 2007;116:249-65.
58. Adcock IM, Ito K, Barnes PJ. Histone deacetylation: an important mechanism in inflammatory lung diseases. COPD 2005;2:445-55.
59. Chong DL, Sriskandan S. Pro-inflammatory mechanisms in sepsis. Contrib Microbiol 2011;17:86-107.
60. Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 2003;101:3765-77.
61. Yu J, Ma Z, Shetty S, Ma M, Fu J. Selective HDAC6 inhibition prevents TNF-alpha-induced lung endothelial cell barrier disruption and
endotoxin-induced pulmonary edema. Am J Physiol Lung Cell Mol Physiol 2016;311:L39-47.
62. Yu J, Ma M, Ma Z, Fu J. HDAC6 inhibition prevents TNF-alpha-induced caspase 3 activation in lung endothelial cell and maintains
cell-cell junctions. Oncotarget 2016;7:54714-22.
63. Ni YF, Wang J, Yan XL, Tian F, Zhao JB, Wang YJ, Jiang T. Histone deacetylase inhibitor, butyrate, attenuates lipopolysaccharide-
induced acute lung injury in mice. Respir Res 2010;11:33.
64. Zhang L, Jin S, Wang C, Jiang R, Wan J. Histone deacetylase inhibitors attenuate acute lung injury during cecal ligation and puncture-
induced polymicrobial sepsis. World J Surg 2010;34:1676-83.
65. Kasotakis G, Galvan MD, Osathanugrah P, Dharia N, Bufe L, Breed Z, Mizgerd JP, Remick DG. Timing of valproic acid in acute lung
injury: prevention is the best therapy? J Surg Res 2017;220:206-12.
66. Kasotakis G, Galvan M, King E, Sarkar B, Stucchi A, Mizgerd JP, Burke PA, Remick D. Valproic acid mitigates the inflammatory
response and prevents acute respiratory distress syndrome in a murine model of Escherichia coli pneumonia at the expense of bacterial
clearance. J Trauma Acute Care Surg 2017;82:758-65.
67. Wu SY, Tang SE, Ko FC, Wu GC, Huang KL, Chu SJ. Valproic acid attenuates acute lung injury induced by ischemia-reperfusion in
rats. Anesthesiology 2015;122:1327-37.
68. Lu W, Yao X, Ouyang P, Dong N, Wu D, Jiang X, Wu Z, Zhang C, Xu Z, Tang Y, Zou S, Liu M, Li J, Zeng M, Lin P, Cheng F, Huang
J. Drug repurposing of histone deacetylase inhibitors that alleviate neutrophilic inflammation in acute lung injury and idiopathic